Biomea Fusion, Inc.
BMEA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840439
No open-market purchases or sales by Biomea Fusion, Inc. insiders were filed in the last 90 days; 61 institutions reported holding it in 13F filings for Q2 2026, worth $36.8M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −4 vs. previous quarter
- 61
- 13F valueReported value at the end of Q2 2026
- $36.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding BMEA, Q2 2026
No superinvestor reported holding BMEA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Biomea Fusion, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 15, 2025 (view filing) | Dec 11 | 4 days | Erdtmann Rainer MSee Remarks | PPurchase | +30.0K | $1.43 | +$42.9K | +4.3%723.0K after | |
| Dec 4, 2025 (view filing) | Dec 2 | 2 days | Hitchcock Michael J.M.Interim CEO | PPurchase | +100.0K | $0.99 | +$99.0K | +666.7%115.0K after | |
| Dec 2, 2025 (view filing) | Nov 28-Dec 1 | 4 days | Erdtmann Rainer MSee Remarks | PPurchase | +50.0K | $1.09 | +$54.5K | +7.8%693.0K after | 2 lots |
| Oct 1, 2024 (view filing) | Sep 30 | 1 day | Hitchcock Michael J.M.Director | PPurchase | +10.0K | $10.06 | +$100.6K | +200.0%15.0K after | |
| Jun 12, 2024 (view filing) | Jun 11 | 1 day | Valle FrancoChief Financial Officer | PPurchase | +12.5K | $4.43 | +$55.4K | +41.7%42.5K after | |
| Jun 2, 2023 (view filing) | May 31-Jun 1 | 2 days | A2A Pharmaceuticals, Inc.10% Owner | SSale | −125.0K | $34.11 | −$4.26M | −3.4%3.50M after | 2 lots |
| May 17, 2023 (view filing) | May 12 | 5 daysLate | A2A Pharmaceuticals, Inc.10% Owner | SSale | −25.0K | $33.84 | −$846.0K | −0.7%3.63M after | |
| May 10, 2023 (view filing) | May 8-9 | 2 days | A2A Pharmaceuticals, Inc.10% Owner | SSale | −250.0K | $34.30 | −$8.57M | −6.4%3.65M after | 2 lots |
| Apr 26, 2023 (view filing) | Apr 20 | 6 daysLate | A2A Pharmaceuticals, Inc.10% Owner | SSale | −200.0K | $29.12 | −$5.82M | −4.9%3.90M after | |
| Apr 6, 2023 (view filing) | Mar 31 | 6 days | A2A Pharmaceuticals, Inc.10% Owner | SSale | −200.0K | $31.25 | −$6.25M | −4.7%4.10M after | Amended |
Top 10 13F holders, Q2 2026
The largest institutional positions in Biomea Fusion, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 8,814,946 | $13.0M | 0.00% | +1,5870.0% | Added |
| Vanguard Capital Management LLC | 2,829,927 | $4.16M | 0.00% | +232,627+9.0% | Added |
| Marshall Wace, LLP | 2,049,802 | $3.01M | 0.00% | +851,251+71.0% | Added |
| Aisling Capital Management LP | 2,048,757 | $3.01M | 0.64% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 1,455,474 | $2.14M | 0.00% | +142,676+10.9% | Added |
| Fideuram - Intesa Sanpaolo Private Banking S.P.A. | 723,176 | $1.06M | 0.03% | +166,140+29.8% | Added |
| BlackRock, Inc. | 715,445 | $1.05M | 0.00% | +74,010+11.5% | Added |
| Geode Capital Management, LLC | 708,854 | $1.04M | 0.00% | +160,668+29.3% | Added |
| Susquehanna International Group, LLP | 612,735 | $900.7K | 0.00% | −17,130−2.7% | Reduced |
| Mariner, LLC | 594,726 | $874.2K | 0.00% | −59,852−9.1% | Reduced |